Evidence map›Paper›PMID 36269032›Full record

ArticlePharmaceutical biology2022

A clinical herbal prescription Gu-Shu-Kang capsule exerted beneficial effects on the musculoskeletal system of dexamethasone-treated mice by acting on tissue IGF-1 signalling pathway.

Xiao-Li Li, Liang Wang, Ming-Chao He, Wen-Xiong Li, Jia-Li Zhang, Yong-Fang Fu, Yan Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Xiao-Li LiSchool of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai, China.
Liang WangDepartment of Geriatric, The Eighth Medical Center of PLA General Hospital, Beijing, China.
Ming-Chao HeSpine Disease Research Institute, Longhua Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Wen-Xiong LiSpine Disease Research Institute, Longhua Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jia-Li ZhangSpine Disease Research Institute, Longhua Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yong-Fang FuSpine Disease Research Institute, Longhua Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yan ZhangSpine Disease Research Institute, Longhua Hospital, Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextGu-Shu-Kang (GSK) is a clinical traditional Chinese medicine prescription for the treatment of primary osteoporosis.

objectiveThis study investigates the protection of GSK against dexamethasone (Dex)-induced disturbance of musculoskeletal system in male mice and to identify the underlying mechanism. MATERIALS AND

methodsMale C57BL/6 mice in Dex-treated groups were orally administered (i.g.) with vehicle, low dose (0.38 g/kg), middle dose (0.76 g/kg), or high dose (1.52 g/kg) of GSK for 8 weeks. A control group was designed without any treatment. The quadriceps femoris, tibialis anterior and gastrocnemius were harvested. Molecular expression was determined by RT-PCR and immunoblotting.

resultsTreatment with GSK enhanced weight-loaded swimming time (from 411.7 ± 58.4 s in Dex group to 771.4 ± 87.3 s in GSK-M) and grip strength (from 357.8 ± 23.9 g in Dex group to 880.3 ± 47.6 g in GSK-M). GSK produced a rise in cross-sectional area of myofibers and promoted a switching of glycolytic-to-oxidative myofiber. The administration with GSK affected expression of muscle regulatory factors shown by the down-regulation in MuRF-1 and atrogin-1 and the up-regulation in myogenic differentiation factor (MyoD) and myosin heavy chain (MHC). GSK stimulated tissue IGF-1 signalling pathway (IGF-1R/PI3K/Akt), not only in skeletal muscle but also in bone associated with the amelioration of trabecular bone mineral density and the improvement of osteogenesis.

conclusionsThese findings revealed the potential mechanisms involved in the beneficial effects of Gu-Shu-Kang on musculoskeletal system in mice with challenging to dexamethasone, and this prescription may have applications in management for muscle atrophy and osteoporosis triggered by glucocorticoid.

Indexed as

Drugs, Chinese HerbalGlucocorticoidsMuscle, SkeletalAnimalsDexamethasoneInsulin-Like Growth Factor IMaleMiceMice, Inbred C57BLMyosin Heavy ChainsOsteoporosisPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktDexamethasoneDrugs, Chinese HerbalGlucocorticoidsInsulin-Like Growth Factor IMyosin Heavy ChainsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktBonemusclemuscle atrophymyofiberosteoporosis

Identifiers

PMID36269032
PMCPMC9590446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.